Attitudes to early rheumatoid arthritis: Changing patterns. Results of a survey

Annals of the Rheumatic Diseases

Volumn 63, Issue 10, 2004, Pages 1269-1275

  Aletaha, D ^a   Eberl, G ^b   Nell, V P K ^a   Machold, K P ^a   Smolen, J S ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CYCLIC CITURLLINATED PEPTIDE ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PEPTIDE ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ATTITUDE; BONE EROSION; DIAGNOSTIC APPROACH ROUTE; DISEASE DURATION; FOLLOW UP; HEALTH SURVEY; HUMAN; MONARTHRITIS; NORMAL HUMAN; PATIENT REFERRAL; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SERODIAGNOSIS; SYMPTOM; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATTITUDE OF HEALTH PERSONNEL; BIOLOGICAL MARKERS; HEALTH CARE SURVEYS; HUMANS; LONG-TERM CARE; PROFESSIONAL PRACTICE; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RHEUMATOID FACTOR; SEROLOGIC TESTS;

EID: 4644360558     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.015131     Document Type: Review

References (33)

1. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl 1996;44:13-22.
2. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
3. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
4. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol Suppl 1990;22:12-15.
5. O'Dell JR. The therapeutic pyramid: a work in progress. J Rheumatol 1997;24:1028-30.
6. Wilske KR, Healey LA. Remodeling the pyramid-a concept whose time has come. J Rheumatol 1989;16:565-7.
7. Arnetf FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
9. Nell VPK, Machold KP, Eberl G, Stamm T, Uffmann M, Smolen JS. The Benefit of very early referral and therapy with disease modifying antirheumatic drugs in patients with early rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46(suppl 9):S334.
10. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003;48:46-53.
11. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54;944-7.
12. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
13. Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, et al. Very recent onset arthritis-clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002;29:2278-87.
14. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis 2002;61:630-4.
15. Silman AJ, Symmons DP. Selection of study population in the development of rheumatic disease criteria: comment on the article by the American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1995;38:722-3.
16. Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand 1940;17:172-88.
17. Vincent C, Serre G, Lapeyre F, Fournie B, Ayrolles C, Fournie A, et al. High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies'. Ann Rheum Dis 1989;48:712-22.
18. Janssens X, Veys EM, Verbruggen G, Declercq L. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol 1988;15:1346-50.
19. Hassfeld W, Steiner G, Graninger W, Witzmann G, Schweitzer H, Smolen JS. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993;32:199-203.
20. Simon M, Girbal E, Sebbag M, Gomes-Daudrix V, Vincent C, Salama G, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993;92:1387-93.
21. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
22. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000;43:1809-19.
23. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
24. Tsakorras E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000;27:623-9.
25. Andersen JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
26. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
27. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasolazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
28. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
29. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
30. Harrison B, Symmons D. Early inflammatory polyarthritis: results from the Norfolk Arthritis Register with a review of the literature. II. Outcome at three years. Rheumatology (Oxford) 2000;39:939-49.
31. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
32. Verstappen SM, Jacobs JW, Biilsma JW, Heurkens AH, Booma-Frankfort C, Borg EJ, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48:1797-807.
33. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48:1771-4.